In this video, Michael Schweizer, MD, discusses the background, findings, and takeaways of the study, “Bipolar androgen therapy (BAT) plus Olaparib in men with metastatic castration-resistant prostate cancer (mCRPC),” presented recently at the 2021 European Society for Medical Oncology Annual Meeting. Schweizer is an associate professor in the division of medical oncology at the University of Washington and an associate professor in the clinical research division at the Fred Hutchinson Cancer Research Center, Seattle, Washington
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.